FDA Approves Mounjaro to Reduce Cardiovascular Risk in Type 2 Diabetes
The FDA approved Mounjaro on September 2, 2026, for a new indication: reducing cardiovascular risk in adults with type 2 diabetes. A major clinical trial found the drug performed as well as Trulicity in protecting heart health.
The Food and Drug Administration approved Mounjaro on September 2, 2026, for a new use: reducing the risk of major cardiovascular events in adults with type 2 diabetes.
The approval adds a heart-protection indication to Mounjaro, which was already approved for blood sugar control and weight loss. The FDA based the decision on results from a large clinical trial showing the drug performed as well as Trulicity, an established diabetes medication, in protecting heart health.
Mounjaro, made by Eli Lilly, belongs to a class of drugs called GLP-1 receptor agonists. These medications work by mimicking hormones that regulate blood sugar and appetite. Several drugs in this class have now received cardiovascular approvals, reflecting growing evidence that they offer benefits beyond glucose control.
Type 2 diabetes significantly raises the risk of heart attack, stroke, and other cardiovascular events. Doctors say having a drug that addresses both blood sugar and heart risk in a single medication simplifies treatment for many patients.
The new indication means Mounjaro can now be prescribed specifically for cardiovascular risk reduction, which may affect insurance coverage and prescribing decisions for patients who have diabetes and established heart disease.
Eli Lilly said the approval reflects the drug's broad clinical profile. Mounjaro is already one of the most prescribed diabetes and weight-loss medications in the United States.
